■Talquetamab是用于复发性/难治性多发性骨髓瘤的首类GPRC5DxCD3双特异性抗体。鉴于现实世界的数据有限,这项研究是与美国医疗保健提供者(HCP)一起进行的,目的是了解真实世界的talquetamab给药和症状管理.
■在2024年2月/3月,对在现实世界中使用talquetamab的HCP进行了个人深度访谈(IDIs;n=10)。随后的专家小组(n=6)进一步讨论了当前的做法。
■IDI报告了各种逐步加药(SUD)的设置,包括住院患者(n=5),门诊(n=3),和混合模型(n=2),趋势是缩短SUD长度,以减少医疗资源的利用率。大多数HCP在SUD(n=7)和治疗阶段(n=8)中使用双周(Q2W)时间表。八名参与者探讨了在疾病对治疗反应阳性后,将患者的剂量频率降低至每4周(Q4W),考虑到患者的便利性和缓解GPRC5D相关症状。小组成员推荐了症状管理和预防策略,如地塞米松和制霉菌素漱口水或锌和维生素B复合物用于口腔症状,以及皮肤和指甲症状的局部类固醇和化妆品。
■本研究概述了talquetamab当前的现实实践。研究结果表明SUD护理设置存在差异。0.8mg/kgQ2W给药方案是最常见的,尽管对于一些对治疗有反应的患者,改用Q4W是一种现实世界的症状管理策略。与GPRC5D相关的症状管理方法正在发展;预防性使用地塞米松和制霉菌素漱口水或锌和维生素B复合物可能是缓解口腔症状的有效策略。需要进一步的现实证据来告知最佳给药时间表,同时减轻症状影响。
Talquetamab是一种新疗法,于2023年在美国被批准用于一种称为多发性骨髓瘤的血癌。这种药物以两种剂量中的一种给药,每个方案包括明确的逐步给药方案,患者首先接受较少量的药物以帮助避免严重的副作用.因为talquetamab是新的,并且与治疗相关的症状相关,在其他多发性骨髓瘤治疗中通常看不到,医生和患者需要更多的药物管理和症状管理指导。在这项研究中,我们描述了与有使用talquetamab经验的医疗保健专业人员进行访谈和专家小组讨论的结果.这项研究发现,大多数医疗保健专业人员对在医院过夜的患者进行了逐步加药,而其他提供者在门诊就诊时给予这些剂量。大多数提供者在使用相关的逐步给药方案后每2周施用一次talquetamab。此外,医疗保健提供者描述了一些病人的过渡,对治疗有积极反应的人,减少每月一次的给药频率,以帮助减少治疗相关症状的影响。专家小组的参与者描述了管理或预防这些症状的方法,如地塞米松和制霉菌素漱口水或锌和维生素B复合物用于口腔症状,以及皮肤和指甲症状的局部类固醇和化妆品。总之,这项研究提供了有经验的医疗服务提供者使用talquetamab治疗多发性骨髓瘤患者的有价值的真实信息.
UNASSIGNED: Talquetamab is the first-in-class GPRC5DxCD3 bispecific antibody for relapsed/refractory multiple myeloma. Given limited real-world data, this study was conducted with US healthcare providers (HCPs) to understand real-world talquetamab dosing and symptom management.
UNASSIGNED: In February/March 2024, individual in-depth interviews (IDIs; n = 10) were conducted with HCPs administering talquetamab in real-world settings. A subsequent expert panel (n = 6) further discussed current practices.
UNASSIGNED: The IDIs reported a variety of settings for step-up dosing (SUD), including inpatient (n = 5), outpatient (n = 3), and hybrid models (n = 2), with a trend toward shorter SUD length to reduce healthcare resource utilization. Most HCPs used a biweekly (Q2W) schedule in SUD (n = 7) and treatment phases (n = 8). Eight participants explored reducing dose frequency to every 4 weeks (Q4W) in patients following positive disease response to treatment, considering patient convenience and relieving GPRC5D-related symptoms. Panelists recommended symptom management and prophylactic strategies, such as dexamethasone and
nystatin mouthwash or zinc and vitamin B complex for oral symptoms, and topical steroids and cosmetic products for skin and nail symptoms.
UNASSIGNED: This study outlines current real-world practices for talquetamab. Findings indicate variation in the SUD care setting. The 0.8 mg/kg Q2W dosing schedule was most common, although switching to Q4W is a real-world symptom management strategy for some patients with responses to therapy. GPRC5D-related symptom management approaches are evolving; prophylactic use of dexamethasone and
nystatin mouthwash or zinc and vitamin B complex may be effective strategies to alleviate oral symptoms. Further real-world evidence is needed to inform optimal dosing schedules while mitigating symptom impact.
Talquetamab is a new treatment that was approved in the United States in 2023 for a type of blood cancer called multiple myeloma. This drug is administered at one of two doses, each of which includes a defined step-up dosing schedule where patients first receive smaller amounts of the drug to help avoid serious side effects. Because talquetamab is new and associated with treatment-related symptoms not normally seen with other multiple myeloma treatments, doctors and patients need more guidance on drug administration and symptom management. In this study, we describe findings from interviews and an expert panel discussion with healthcare professionals who have experience using talquetamab. This study found that most healthcare professionals administered step-up dosing with patients staying overnight in the hospital, while other providers administered these doses during outpatient visits. Most providers administered talquetamab once every 2 weeks after utilizing the associated step-up dosing schedule. Additionally, healthcare providers described transitioning some patients, who had responded positively to treatment, to a less frequent dosing schedule of once per month to help reduce the effect of treatment-related symptoms. Participants in the expert panel described approaches for managing or preventing these symptoms, such as dexamethasone and
nystatin mouthwashes or zinc and vitamin B complex for oral symptoms, and topical steroids and cosmetic products for skin and nail symptoms. In summary, this study provides valuable real-world information from healthcare providers who have experience treating patients with multiple myeloma with talquetamab.